Heart failure (HF) ranks among the most costly chronic diseases in developed countries. At
present these countries devote 1–2% of all healthcare expenditures towards HF. In the US …

Aims It remains unclear whether primary prophylactic implantable cardioverter-defibrillator
(ICD) therapy is cost-effective compared with a 'no ICD strategy'in the European health care …

Despite recent advances in healthcare, hypertension is a leading cause of death and
remains a disease burden worldwide. Now in its second edition, the Manual of Hypertension …

Aims To examine long-term healthcare utilization and costs of patients with stable coronary
artery disease (SCAD). Methods and results Linked cohort study of 94 966 patients with …

Background Approximately half of people with heart failure have chronic kidney disease
(CKD). Pharmacological interventions for heart failure in people with CKD have the potential …

Results Patients randomized to darbepoetin alfa reported significant improvements
compared with placebo patients in Functional Assessment of Cancer Therapy-Fatigue, and …

Background There is insufficient evidence whether the benefit of adding angiotensin II
receptor blockers (ARBs) to angiotensin-converting enzyme (ACE) inhibitors outweighs the …

Objective In young spontaneously hypertensive rats (SHR), transient angiotensin II type 1
receptor (AT 1 R) blockade decreases blood pressure for a prolonged period. We tested the …

BACKGROUND: Electronic health records (EHRs), when linked across primary and
secondary care and curated for research use, have the potential to improve our …

Hypertension is one of the leading risk factors for cardiovascular disease and represents a
major health and economic burden. Most patients with high-or very high-risk hypertension …